Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome Academic Article uri icon

Overview

MeSH Major

  • Gastrointestinal Agents
  • Malignant Carcinoid Syndrome
  • Octreotide

abstract

  • Once octreotide steady-state concentrations are achieved, octreotide LAR controls the symptoms of carcinoid syndrome at least as well as SC octreotide. A starting dose of 20 mg of octreotide LAR is recommended. Supplemental SC octreotide is needed for approximately 2 weeks after initiation of octreotide LAR treatment. Occasional rescue SC injections may be required for possibly 2 to 3 months until steady-state octreotide levels from the LAR formulation are achieved.

publication date

  • February 1999

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10080605

Additional Document Info

start page

  • 600

end page

  • 6

volume

  • 17

number

  • 2